# Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

> **NCT04286412** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** Nonacog alfa

## Key facts

- **NCT ID:** NCT04286412
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2020-09-24
- **Final completion:** 2020-09-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04286412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04286412, "Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04286412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*